It's crunch time for biotech projects started on a bet that the industry would shake off its multiyear malaise.

Amid the federal funding uncertainty for health and sciences, local life science leaders say this could be a moment for industry partners, investors and others to step up and support the sector.

Biotech investing can be tricky. Often, the drugs that these fledgling companies produce don’t pan out, and shareholders take ...

The European Commission (EC) announced on January 29, 2025, that it launched a Biotech and Biomanufacturing Hub to support ...

The first clinical trials using organs from genetically modified pigs offer hope to patients with kidney failure, who face a ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...

Invest in SPDR S&P Biotech ETF (XBI) for long-term growth potential and diverse, equal-weighted portfolio in the biotech ...

Don’t look now, but Cathie Wood of Ark Invest is fresh off an impressive comeback year, with her broader basket of disruptive ...

Curie.Bio, the biotech accelerator and investment firm, has raised another $340 million to invest in startups.

United Therapeutics Corp. announced Feb. 4. that it will start a trial in mid-2025 with six patients who have end-stage renal disease. These patients, who have been on dialysis for at least six months ...

Companies added to the blacklist can be subject to fines and other sanctions, including a freeze on trade and a revocation of ...